The global TRIUMPH Phase 3 program is now assessing retatrutide in obesity , type 2 diabetes , obstructive sleep apnea , knee osteoarthritis , and cardiovascular outcomes
Semaglutide GLP-1, a GLP-1 receptor agonist , mimics incretin hormones, enhancing insulin secretion, slowing gastric emptying, and reducing appetite, achieving up to 15% weight loss, with an average reduction of 12.4%
Effect of whey protein supplementation on weight and body composition indicators: A meta-analysis of randomized clinical trials
Accessed August 5, 2025.
Patent estate includes the Roche structure patent agreement ($100M upfront, Jan 2026)
Researchers point to improvements in blood pressure, lipid profiles, and vascular inflammation as key contributors